医学
内科学
心肌梗塞
心源性休克
心脏病学
经皮冠状动脉介入治疗
危险系数
队列
比例危险模型
作者
Bryan Richard Sasmita,Yuansong Zhu,Hongbo Gan,Xiankang Hu,Yuzhou Xue,Zhenxian Xiang,Gang Liu,Suxin Luo,Bi Huang
出处
期刊:Shock
[Ovid Technologies (Wolters Kluwer)]
日期:2021-10-27
被引量:1
标识
DOI:10.1097/shk.0000000000001876
摘要
BACKGROUND Patients with cardiogenic shock (CS) complicating acute myocardial infarction (AMI) are at high risk of death. Inflammation is involved in both CS and AMI, and our present study aimed to investigate the changes of leukocyte and its subtypes as well as their prognostic value in patients with CS complicating AMI. METHODS Data of 217 consecutive patients with CS complicating AMI were analyzed. The primary endpoint was 30-day all-cause mortality. The secondary endpoint was the composite events of major adverse cardiovascular events (MACE) including 30-day all-cause mortality, ventricular tachycardia/ventricular fibrillation, atrioventricular block, gastrointestinal hemorrhage and non-fatal stroke. The association of leukocyte and its subtypes with the endpoints was analyzed by Cox regression analysis. RESULTS Leukocyte and its subtypes including neutrophil, eosinophil, lymphocyte, monocyte and basophil were all statistically significant between survivors and non-survivors (all p 11.6x109/L) (HR 1.815; 95%CI 1.134, 2.903; p = 0.013), low eosinophil ( 11.6x109/L) (HR 1.894; 95%CI 1.285, 2.791; p = 0.001), low eosinophil (<0.3%) (HR 1.729; 95%CI 1.119, 2.670; p = 0.014) and low basophil (≤0.1%) (HR 1.560; 95%CI 1.101, 2.210; p = 0.012) were independently associated with increased risk of 30-day MACE. CONCLUSIONS Leukocyte and its subtypes changed significantly in patients with CS complicating AMI. In addition to leukocyte, eosinophil and basophil also served as independent prognostic factors for 30-day outcomes. Moreover, as the composite of leukocyte and its subtypes increased the predictive power, thus leukocyte and its subtypes, especially eosinophil and basophil should be taken into consideration for the current risk stratification model.
科研通智能强力驱动
Strongly Powered by AbleSci AI